With two retina launches on different timelines, how will the call points and commercial build-out sequence in terms of size and scope?

The new retina assets are a good commercial fit, servicing an underserved population. The call point is more concentrated (about 3,500 retina physicians, with 2,000 likely to prescribe Stargardt therapies), allowing for an efficient launch into this audience. There are synergies between the IRX-101 and ALK-001 target prescribers. The company plans a dedicated sales force of 50-75 individuals for these assets. “And the other thing I'd point out is there's a lot of lads in the call here. So it's about 500 doctors will be serving with IRX-101, that are doing ITs and then a subset of those actually 2,000 are prescribing, we think we're likely to prescribe over 80% of the Stargardt therapies here. So that presents some real synergy in terms of the sales force itself that we'll be building here.”

What is the addressable market size for ALK-001, considering patient care by retinal specialists and potential pricing? How does the company view BCVA changes versus lesion growth, and the need for long-term follow-up for durable BCVA benefit?

The estimated addressable market is 36,000 diagnosed patients and 86,000 total patients in the US. Pricing is considered to be in the $350,000 range, based on value creation and differentiation. The trial showed statistically significant benefit in low-light visual acuity (LLVA) within 2 years, which is a more sensitive measure and a precursor to BCVA loss. The NORTHSTAR trial's primary endpoint is retinal lesion growth, an FDA-accepted endpoint, with a 29% reduction observed in prior trials. “In terms of pricing, that price range that you articulated is the price range that we would consider also for this asset around that $350,000 price point. And it's really about value creation, understanding the differentiated profile here.”

Is there an opportunity for ALK-001 in geographic atrophy (GA)? Is a second Phase III trial for ALK-001 expected to be needed for approval, or is it for commercial/data enhancement purposes?

The acquisition's focus and ascribed value are primarily on Stargardt disease, despite ALK-001 having been studied in GA patients. The current NORTHSTAR Phase III trial is robustly designed for registration and approval. A potential second Phase III trial is being considered for risk mitigation and to enhance data, possibly focusing on younger/faster progressors or including additional exploratory endpoints, rather than being a strict requirement for approval. “The way we think about the second trial is really proactively thinking about any risk mitigation if we need it. And also any potential upside where we could enhance the data, enhance the exercise to stay with the fast progressors or other ways to enhance it. So it's really more of a risk mitigation and potential upside strategy.”

TARS

Tarsus Pharmaceuticals (TARS) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

Tarsus Pharmaceuticals Q2 FY26 — Record XDEMVY Sales and Strategic Acquisition of Alkeus Pharmaceuticals

Tarsus Pharmaceuticals reported a strong second quarter, driven by record sales of XDEMVY, which continues to exceed expectations and is on track for over $2 billion in potential annual peak sales. The company also announced the strategic acquisition of Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a late-stage investigational therapy for Stargardt disease, to its retina pipeline. This move broadens Tarsus's presence in the retina specialty, leveraging XDEMVY's commercial success to fund future growth and build a leading eye care company with multiple potential blockbuster medicines.

Highlights

XDEMVY net product sales reached a record $173.9 million, representing over 69% year-over-year growth and 20% quarter-over-quarter growth.
Full-year XDEMVY net product sales guidance was raised to $685 million to $705 million from $670 million to $700 million.
More than 700,000 patients have been treated with XDEMVY to date, generating almost $1 billion in net product sales.
XDEMVY retreatment rates advanced into the high teens, with expectations to stabilize at 20%.
Unaided awareness of Demodex blepharitis (DB) climbed to approximately 30%, up from 2% at launch, driven by effective consumer campaigns.

Concerns

The increase in full-year R&D expense guidance to $190 million-$210 million (from $115 million-$135 million) reflects the upfront consideration for the iRenix Medical acquisition.
The Alkeus acquisition involves an upfront consideration of $450 million ($270 million cash, $180 million stock) and up to $350 million in potential milestones, impacting near-term cash and stock dilution.

Guidance & targets

Category	Target	Timeline	Confidence
XDEMVY Full-Year Net Product Sales	$685 million to $705 million high materiality	Full-year FY26	High
Gross Margins	approximately 93% medium materiality	Full-year FY26	High
SG&A Expenses	$545 million to $565 million medium materiality	Full-year FY26	High
R&D Expense	$190 million to $210 million high materiality	Full-year FY26	High
ALK-001 NORTHSTAR Phase III Top-Line Results	Second half of 2029 high materiality	H2 2029 · CY29	High
Profitability	Sometime in '27 medium materiality	FY27	Medium

Deals & partnerships

Alkeus Pharmaceuticals Acquisition of Alkeus Pharmaceuticals and its lead asset, gildeuretinol (ALK-001), a late-stage investigational therapy for Stargardt disease. $450 million upfront ($270 million cash, $180 million Tarsus common stock) plus up to $350 million in potential milestones (regulatory approval, first commercial sale) and low single-digit tiered decreasing royalties on future net sales.

The transaction is subject to the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Tarsus secured $125 million through a private placement financing from a syndicate of leading health care investors, including several shareholders of Alkeus.

iRenix Medical Acquisition of iRenix Medical, adding a product to the pipeline. $75 million upfront consideration (reflected in increased R&D guidance).

The acquisition was completed prior to the Alkeus announcement and is part of Tarsus's strategy to expand its pipeline and leadership in eye care.

Risks & headwinds

Seasonal revenue progression for XDEMVY Q3 and Q4 FY26

Tempered growth expected in Q3 FY26, followed by more robust growth in Q4 FY26.

Mitigation:Management's full-year guidance already accounts for this seasonality, which includes fewer physician office visits due to vacations, holidays, and conferences in the summer period, and usual year-end patient dynamics.

Integration risk and financial impact of Alkeus acquisition Near-term and long-term

Upfront consideration of $450 million ($270 million cash, $180 million stock) and up to $350 million in potential milestones.

Mitigation:Tarsus is investing from a position of strength with a robust balance sheet and maintaining financial flexibility. The transaction is expected to close later this year, subject to regulatory approvals. A private placement financing of $125 million was secured to support the acquisition.

Competitive landscape for Stargardt disease Ongoing

Competitor (Belite's tinlarebant) has a head start in Phase III trials.

Mitigation:Tarsus believes ALK-001's differentiated profile (efficacy in atrophy and low-light visual acuity, strong safety profile without impacting visual cycle) will allow it to capture significant market share. The NORTHSTAR trial is already enrolling globally and is expected to be well underway by the time other products might be approved.

What to watch in Q3 FY26

XDEMVY Q3 Revenue Progression

Q3 FY26

Current Q2 FY26 net product sales: $173.9 million

Target Tempered growth due to seasonality

Why it matters

To assess if XDEMVY's quarterly revenue progression aligns with management's expectation of seasonality (tempered Q3, robust Q4) within the raised full-year guidance.

As we have previously discussed, we expect the quarterly revenue progression throughout the remainder of the year to reflect normal seasonality in the eye care market. The summer period typically includes fewer physician office delayed case due to vacations, holidays and conferences, and we expect tempered growth in the [Technical Difficulty].

Find out whether TARS delivers this. Inve re-checks your case every morning.

Q&A highlights

How does ALK-001 compare in efficacy to tinlarebant, especially given its head start? What are the differentiating factors for market share?

ALK-001 offers a unique profile by demonstrating effectiveness in slowing disease progression measured by atrophy and low-light visual acuity, coupled with a strong safety profile over 7 years. Its mechanism reduces toxic dimers without impacting the visual cycle, which is crucial for patients, and it has shown no negative effects on night vision or color vision. Management believes this differentiation makes it a $1 billion+ opportunity.

“So in terms of overall profile, we see something that can really change the course of this disease that demonstrated effectiveness in a couple of dimensions that are really important patients, both the progression of disease is measured by atrophy and the progression of disease measured by visual acuity, low-light visual acuity in particular. And that's unique in this field.”

asked by Ryan Ries · answered by Bobak Azamian

3 min read 6 chapters

Detailed narrative

XDEMVY Commercial Momentum and Market Penetration

XDEMVY continues to demonstrate exceptional commercial performance, with Q2 net product sales reaching $173.9 million, marking a 69% YoY and 20% QoQ growth. The company has treated over 700,000 patients to date, generating nearly $1 billion in net product sales.

Eye care professionals (ECPs) are increasingly adopting XDEMVY, with the number of ECPs prescribing at a near-daily cadence doubling over the past year. Retreatment rates are advancing into the high teens, expected to stabilize at 20%, indicating sustained demand for the product.

Strategic Acquisition of Alkeus Pharmaceuticals and ALK-001

Tarsus announced the acquisition of Alkeus Pharmaceuticals and its lead asset, gildeuretinol (ALK-001), a late-stage investigational therapy for Stargardt disease. This acquisition broadens Tarsus's presence in the retina specialty, complementing the earlier acquisition of IRX-101. ALK-001 is positioned to become a foundational treatment for Stargardt disease, a devastating inherited retinal disease with no FDA-approved treatments, affecting an estimated 86,000 patients in the US.

ALK-001 Clinical Profile and Market Opportunity

ALK-001 is a modified vitamin A analog designed to slow the formation of toxic vitamin A dimers, which cause Stargardt disease, while preserving the normal visual cycle. Clinical evidence from TEASE studies showed potential to preserve visual function and acuity, slow retinal atrophy, and demonstrated a favorable long-term tolerability profile over 7 years in more than 400 patients.

The ongoing NORTHSTAR Phase III study aims to confirm these benefits, with top-line results expected in H2 2029. Management estimates ALK-001 represents a $1 billion+ opportunity, with potential pricing in the $350,000 range.

Commercial Strategy for Retina Portfolio

Tarsus plans to apply its commercial execution playbook to the new retina assets, focusing on a more concentrated physician base of approximately 3,500 retina specialists. The strategy involves delivering strong scientific evidence, securing broad access, and launching efficiently. There are anticipated synergies in the sales force, as a subset of the 500 doctors treating IRX-101 patients are also expected to prescribe Stargardt therapies.

The company is considering a dedicated sales force of 50-75 individuals for the new retina assets.

Consumer Engagement and Awareness for XDEMVY

Tarsus's consumer campaigns, featuring celebrity spokesperson John Cena and the 'Barry the Cat' DTC campaign, have significantly increased unaided awareness of Demodex blepharitis to 30%. Website engagement on XDEMVY.com has increased by 19%, with patients actively using tools like 'Find a Doctor' and the AI-powered concierge.

These efforts are successfully driving patients to seek care and ask for XDEMVY by name, reinforcing the top of the funnel for market expansion.

Financial Outlook and Capital Allocation

Tarsus ended Q2 with $449.7 million in cash, cash equivalents, and marketable securities. The company increased its full-year XDEMVY net product sales guidance to $685 million-$705 million. Full-year R&D expense guidance was raised to $190 million-$210 million due to the iRenix acquisition, while SG&A and gross margin expectations remain consistent.

The Alkeus acquisition, valued at $450 million upfront plus milestones, is financed through cash and stock, with an additional $125 million from a private placement, demonstrating disciplined capital allocation to strengthen the long-term growth profile.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.